Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients.
Andrea De GiglioChiara DeianaAlessandro Di FedericoPublished in: Journal of cancer research and clinical oncology (2022)
MDA criteria represent a reliable tool in assessing bone-specific response, offering a more accurate evaluation with the aim to earlier predict survival outcomes or treatment failure compared to RECIST criteria for advanced NSCLC patients receiving immunotherapy.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- small cell lung cancer
- end stage renal disease
- bone mineral density
- newly diagnosed
- ejection fraction
- breast cancer cells
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- high resolution
- postmenopausal women
- patient reported outcomes
- body composition
- mass spectrometry
- pi k akt